- Home
- / PHARMICELL
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
PHARMICELL financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩5 K
2024-10-29
Market Capitalization
₩300 B
2024-10-29
Revenue
₩56.2 B
FY, 2023
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 28.4B | 32.5B | 37.8B | 50.9B | 60.2B | 56.2B |
| Cost of goods sold | 13.7B | 15.5B | 15.8B | 22.7B | 27.5B | 38.4B |
| Gross profit | 14.8B | 17.2B | 22.1B | 28.6B | 33.4B | 22.6B |
| Gross profit margin, % | 52.1% | 53.0% | 58.7% | 56.1% | 55.4% | 40.1% |
| Operating expense total | 12.8B | 13.4B | 13.2B | 18.8B | 22.2B | 13.7B |
| Depreciation and amortization | 14.7B | 1.6B | 2.3B | 1.7B | 2.5B | 3.1B |
| EBITDA | 2.0B | 3.8B | 9.0B | 9.8B | 11.2B | 8.9B |
| EBITDA margin, % | 6.9% | 11.7% | 23.8% | 19.2% | 18.6% | 15.8% |
| EBIT | (12.8B) | 2.1B | 6.6B | 7.9B | 8.2B | 5.7B |
| EBIT margin, % | -45.3% | 6.5% | 17.6% | 15.5% | 13.7% | 10.1% |
| Interest income | 164.8M | 217.0M | 166.4M | 197.4M | 330.8M | 273.8M |
| Interest expense | 56.8M | 101.3M | 84.9M | 1.7B | 746.2M | 866.9M |
| Pre tax profit | (12.7B) | 2.4B | 5.2B | 9.5B | 6.0B | 4.7B |
| Income tax expense | (4.9B) | 1.2B | ||||
| Net Income | (12.7B) | 2.4B | 5.2B | 9.5B | 10.9B | 3.6B |